ME/CFS turns an Olympic sprinter’s recovery into a life spent mostly in bed
Beth Dobbin once trained and raced at the highest level of athletics. At 32, she now spends more than 22 hours a day in bed, leaving her room only to eat and use the bathroom. The shift from Olympic sprinter to someone too unwell to sit up for long captures the severity of ME, also known as myalgic encephalomyelitis or chronic fatigue syndrome.
Her description is stark because the illness is stark. A short conversation, bright light, or loud sound can trigger a crash that lasts for days, and in some cases for months. This pattern is one of the defining features of the disease: exertion, sensory stimulation, and even routine social contact can worsen symptoms instead of improving them.
Dobbin says the illness began after back-to-back Covid and glandular fever infections in the winter of 2021-22. She was not aware she had been unwell with either infection at the time, learning of them only through retrospective tests. What followed was not an abrupt collapse but a slow erosion of capacity—more sleep, slightly slower running times, sore glands in the neck and armpits, and a persistent sense that something was wrong.
Post-viral symptoms spread across multiple body systems
The early phase was easy to misread. British Athletics doctors ran tests without finding a clear explanation, and Dobbin kept training while assuming the lingering effects of glandular fever would fade. She still qualified for the World Championships, Commonwealth Games and European Championships in a compressed season created by the pandemic backlog. Elite performance can hide illness for a time, especially when determination and conditioning mask the first signs of systemic disease.
The mask did not hold.
By the World Championships, she was dealing with a painful throat and abnormal waking during the night. At the Commonwealth Games, she felt dizzy while running and more sore than expected. At the European Championships, she false-started after losing all feeling in her legs while in the blocks. That sequence reads less like isolated bad luck and more like the progressive failure of a body unable to recover between stressors.
After that season ended, the symptoms continued to pile up. Dobbin says she was struggling to stand, sleeping for long stretches, and spending most of her time in bed. After six weeks away from training, she returned for three weeks before doctors were again left with the same conclusion: the illness was affecting multiple systems, and the pattern fit ME.
The condition can involve more than 200 symptoms, including pain, nausea, headaches, brain fog, poor cognitive function, sleep disturbance and severe persistent fatigue that does not improve with rest. In many patients, the central problem is not simple exhaustion but post-exertional symptom exacerbation: the body reacts badly to activity that should be manageable. A short appointment, a blood test, or a conversation can produce a delayed deterioration that is out of proportion to the trigger.
Why the label matters to patients who are not “just tired”
Dobbin rejects the label chronic fatigue syndrome. Her objection is rooted in lived experience, but it also reflects a broader clinical problem. Fatigue is common, broad, and often reversible; ME/CFS is a disabling multisystem illness that can leave patients housebound or bedbound for prolonged periods. For someone who spent years balancing training with eight-hour shifts before turning professional, the word fatigue feels inadequate to describe a body that seems to be shutting down.
“I wish it was just fatigue,” she says. “That would be a walk in the park.”
There is no known cure and no specific treatment. Many patients rely on off-label medication to ease selected symptoms, rather than on a therapy that alters the disease itself. The absence of a targeted treatment leaves supportive care, symptom management, and pacing strategies as the mainstays, while patients and families navigate a condition that can vary widely in severity.
Dobbin now says she often feels too unwell to sleep, despite spending nearly the whole day in bed. Medication helps her rest, but it does not remove the illness. Even sitting up for long periods can be draining, so she stays propped up in bed when she can. The goal is not comfort in the usual sense; it is simply to reduce the intensity of symptoms enough to get through the day.
Family caregiving fills the gap left by limited services
Her family’s account reveals the other half of the disease burden: the hidden work of caring for someone with a chronic illness that has few specialist pathways. Her father says he would take her anywhere if it might help, but there is nowhere to send her. Her mother describes the daily sadness of watching a daughter who should be building her life instead trying to get through each day. Both parents describe the absence of clear NHS referral routes and the frustration of being left in a system with limited expertise, limited services and limited answers.
Dobbin waited 22 months for a face-to-face appointment with a private specialist she arranged herself after British Athletics funding ended. During that period, she found herself educating GPs about the condition. That reversal—patient teaching clinician—speaks to how uneven knowledge remains around ME, even as the disease affects hundreds of thousands in the UK.
Estimates suggest more than 400,000 people in the UK may have ME, and the true number could exceed one million. Severity ranges from people who can still work or study to those requiring round-the-clock care and tube feeding. The illness does not move through a single predictable course, and that variability often delays recognition until function has already fallen sharply.
Long Covid has pushed ME/CFS back into view
Since the Covid pandemic and the rise of long Covid, attention to ME has increased, along with research funding. The overlap in symptoms has brought a difficult but useful visibility to a condition that had long been pushed to the margins of medicine. Researchers and clinicians are now forced to confront the same cluster of post-viral symptoms that patients had been describing for years.
Dobbin sees that shift as one of the few positive developments in a bleak picture. She speaks with a bluntness that comes from knowing the likely consequences of overexertion, including the possibility that this interview itself could worsen her health later. Yet she chose to speak because athletes are often believed more readily than ordinary patients, and because her platform may help others who are dismissed as lazy, unfit or overly anxious.
Her sister plans to run the Yorkshire Marathon to raise money for ME Research UK. It is a small act against a large problem. For now, Dobbin’s future remains uncertain, and the central clinical question is painfully basic: how to diagnose earlier, support better, and develop treatments that do more than manage fragments of a disease that can dismantle a life one symptom at a time.